|
|
| Anti-CD19-CAR / Beijing Doing Biomedical (0 Trials) |
|
| anti-CD19-CAR γδT / Beijing Doing Biomedical (0 Trials) |
|
| anti-CD19-CD137 CAR-T therapy / Sinobioway (0 Trials) |
|
| anti-CD19/22 CART cell therapy / AbelZeta Pharma (0 Trials) |
|
| anti-CD19/BCMA CAR-T cells / Hrain Biotech (0 Trials) |
|
| anti-CD19/CD20 CAR-T cell therapy / Juventas Cell Therapy (0 Trials) |
|
| Anti-CD19/CD20/CD22 CAR T-Cells / The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Instit (0 Trials) |
|
| anti-CD19/CD20/CD22 CAR-T Cells / Affiliated Hospital of Xuzhou Medical University (0 Trials) |
|
| anti-CD19/CD22 CAR-T cells / Hrain Biotech (0 Trials) |
|
| anti-CD19/CD22 CAR-T cells / Shanghai Public Health Clinical Center (0 Trials) |
|
| anti-CD20 mAb / Biocad (0 Trials) |
|
| anti-CD22 ADC / BMS (0 Trials) |
|
| Anti-CD22 CAR NK Cells / Allife Medical Science and Technology (0 Trials) |
|
| anti-CD22 CAR T / National Cancer Institute (0 Trials) |
|
| anti-CD22 CAR-T cell therapy / Shanghai Yake Biotech (0 Trials) |
|
| Anti-CD22 CAR-T Cells / Beijing Boren Hospital (0 Trials) |
|
| anti-CD22 CAR-T therapy / Wuhan Bio–Raid (0 Trials) |
|
| anti-CD22-CAR / Kecellitics Biotech (0 Trials) |
|
| anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells / National Cancer Institute (0 Trials) |
|
| anti-CD3+glycolipid / Harvard Medical School, Hadassah Medical Organization (0 Trials) |
|
| anti-CD3/anti-CD7 ricin A immunotoxin / Novasep (0 Trials) |
|
| anti-CD30 CAR T cells / Wuhan Bio–Raid (0 Trials) |
|
| Anti-CD33 CAR NK Cells / Sichuan Kelun Pharma (0 Trials) |
|
| anti-CD33 CAR T / City of Hope, National Cancer Institute (0 Trials) |
|
| anti-CD33 CAR-NK cells / PersonGen Biomedicine (0 Trials) |
|
| anti-CD38 A2 CAR-T cells / Celularity, Sorrento (0 Trials) |
|
| anti-CD4 802-2 / Theriva Bio (0 Trials) |
|
| anti-CD47 monoclonal antibody / Biocad (0 Trials) |
|
| anti-CD7 CAR-pNK cells / PersonGen Biomedicine (1 Trials) |
|
| anti-CD7 CAR-T cell therapy / Shanghai Yake Biotech (0 Trials) |
|
| anti-CD7 CAR-T cells / Institute of Hematology and Blood Diseases Hospital (0 Trials) |
|
| anti-CD79b/CD3 TDB / Roche (0 Trials) |
|
| anti-CD96 antibody / Samyang Group (0 Trials) |
|
| Anti-CEA-CAR T / Southwest Hospital (1 Trials) |
|
| Anti-CEA-CAR T / Huadao (Shanghai) Biopharmaceutical (0 Trials) |
|
| anti-Claudin 18.2 CAR-T cell therapy / First Affiliated Hospital Xi'an Jiaotong University, Legend Biotech (0 Trials) |
|
| anti-coronavirus antibodies / A.O. Ospedale Papa Giovanni XXIII (0 Trials) |
|
| anti-COVID-19 mAb / Halberd (0 Trials) |
|
| anti-COVID-19 peptide / Nuritas (0 Trials) |
|
| anti-COVID-19 Spike protein monoclonal antibody / Halberd, Arizona State University (0 Trials) |
|
| Anti-CTLA4 AbEnAds antibody / Akamis Bio (0 Trials) |
|
| anti-CTLA4 monoclonal antibody / Aida Pharma (0 Trials) |
|
| anti-CTLA4 scFv / Anaeropharma Science (0 Trials) |
|
| anti-DLL4 antibody / Exelixis, Roche (0 Trials) |
|
| anti-EGFR CAR-T / CARsgen (0 Trials) |
|
| anti-EGFRvIII CAR T cell therapy / Suzhou Maximum Bio-tech (0 Trials) |
|
| anti-EGFRVIII CAR-T cell therapy / Shanghai Unicar (0 Trials) |
|
| Anti-EphA2 CAR-T therapy / SenlangBio (0 Trials) |
|
| anti-EphA2 conjugated bispecific 5'ppp-siPLK1 / Sanofi (0 Trials) |
|
| anti-FGFR-3 HuCAL antibody / Novartis (0 Trials) |
|
| anti-flagellin monoclonal antibody (INO-741) / Rocket Pharma (0 Trials) |
|
| anti-folate receptor beta antibodies (IP 1001E) / Roche (0 Trials) |
|
| anti-FR alpha peptide vaccine / GemVax & KAEL (0 Trials) |
|
| anti-GD2 CAR-T cell therapy / Bellicum, National Cancer Institute (0 Trials) |
|
| anti-GD2 CAR-T cell therapy / Pell Bio-Med Techno (0 Trials) |
|
| Anti-HER2 CAR-T / UTC Therap (0 Trials) |
|
| anti-HGF (hu)mAb 2.12.1 / Amgen (0 Trials) |
|
| anti-HGF (hu)mAb 2.4.4 / Amgen (0 Trials) |
|
| Anti-HMBG1 Mab / Chiesi (0 Trials) |
|
| anti-IFN α receptor mAb / Roche (0 Trials) |
|
| anti-IL-4RA SNA / Exicure (0 Trials) |
|
| anti-IL1RAP / Larix Biosci (0 Trials) |
|
| anti-IL23 / Perrigo Company, Archemix (0 Trials) |
|
| anti-infective bacteriophage therapy (PP-1231) / PHAXIAM Therap (0 Trials) |
|
| anti-infective bacteriophages (PP-2351) / PHAXIAM Therap (0 Trials) |
|
| anti-infective therapeutics / AiCuris, Ligand (0 Trials) |
|
| anti-integrin αvβ5 mAb / Biogen (0 Trials) |
|
| anti-KRAS G12D mTCR PBL / Gilead, National Cancer Institute - Bethesda (0 Trials) |
|
| anti-L1CAM ADC / Elthera (0 Trials) |
|
| Anti-L1CAM radioligand / CIS Pharma (0 Trials) |
|
| anti-LAG-3 mAb / North Coast Biologics (0 Trials) |
|
| anti-LAG-3 sd-rxRNA / Phio Pharma (0 Trials) |
|
| Anti-LAG3 antibody / Zhejiang Huahai Pharma (0 Trials) |
|
| anti-LeY- scFv-CD28-ζ vector / Peter MacCallum Cancer Centre, BMS (3 Trials) |
|
| Anti-MCAM CAR NK / New York Medical College (0 Trials) |
|
| anti-Mesothelin CAR NK Cells / Allife Medical Science and Technology (0 Trials) |
|
| anti-mesothelin CAR T cells / Marino Biotech (0 Trials) |
|
| anti-MSLN-ATI020 / Anwita Biosci (0 Trials) |
|
| anti-MUC1 CAR-pNK cells / PersonGen Biomedicine (1 Trials) |
|
| anti-MUC1 CAR-T cells / PersonGen Biomedicine (2 Trials) |
|
| anti-MUC1 CAR-T cells / Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology (0 Trials) |
|
| Anti-NKG2A PEBL-CAR T / MediSix Therap (0 Trials) |
|
| anti-Notch1NRR antibody / Roche, Exelixis (0 Trials) |
|
| anti-OX40 (CD134) / AstraZeneca (0 Trials) |
|
| Anti-OX40 IgM agonist antibody / IGM Biosciences (0 Trials) |
|
| anti-PD-1 antibody / Tikcro Technologies (0 Trials) |
|
| anti-PD-1 PEBL CAR-T / MediSix Therap (0 Trials) |
|
| anti-PD-1 scFv/anti-CTLA4 scFv / Anaeropharma Science (0 Trials) |
|
| anti-PD-L1 CSR T cells / Marino Biotech (2 Trials) |
|
| anti-PD-L1 therapy / The Wistar Institute (0 Trials) |
|
| anti-PD1 DARPin anticancer therapy / Molecular Partners (0 Trials) |
|
| anti-PD1-CTLA-4 PEBL CAR-T / MediSix Therap (0 Trials) |
|
| anti-pertussis toxin / Sanofi (0 Trials) |
|
| anti-phosphatidylserine monoclonal antibodies / Avid Bioservices, Affitech (0 Trials) |
|
| anti-proliferative therapeutic / Eurofins Discovery (0 Trials) |
|
| Anti-PSMA Designer T Cells / Roger Williams Medical Center (0 Trials) |
|
| anti-PTH1R / Xoma (0 Trials) |
|
| anti-PTK7 allogeneic CAR-T cell therapy / CRISPR Therap (0 Trials) |
|
| anti-rabies serum / Serum Institute of India (0 Trials) |
|
| anti-RANKL monoclonal antibody / Jiangsu Pacific Meinuoke Biopharmaceutical (0 Trials) |
|
| anti-RSV Ab / AIM Therap (0 Trials) |
|
| anti-SARS-CoV-2 convalescent plasma / Mayo Clinic (0 Trials) |
|
| anti-SARS-CoV-2 convalescent plasma / University of Chicago (0 Trials) |
|
| anti-SARS-CoV-2 convalescent plasma / OrthoSera (0 Trials) |
|
| anti-SARS-CoV-2 convalescent plasma / Medical College of Wisconsin (0 Trials) |
|
| anti-SARS-CoV-2 convalescent plasma / Miller School of Medicine, UT Health Science Center, Albert Einstein College of Medicine, NYU Langone Health, Montefiore Health (0 Trials) |
|
| anti-SARS-CoV-2 convalescent plasma / Max Healthcare (0 Trials) |
|
| Anti-SARS-CoV-2 equine immunoglobulin formulation / University of Costa Rica (0 Trials) |
|
| anti-SARS-CoV-2 inactivated convalescent plasma / Shanghai Public Health Clinical Center (0 Trials) |
|
| anti-SARS-CoV-2 virus inactivated plasma / Wuhan University (0 Trials) |
|
| anti-shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment (INM004) / Inmunova (0 Trials) |
|
| anti-siglec-6 CAR-T cell therapy / Xuzhou Medical University (0 Trials) |
|
| anti-SIRPα D-peptide therapeutic / Navigen (0 Trials) |
|
| Anti-SLAMF7 CAR T cells / National Cancer Center, University of Wuerzburg (0 Trials) |
|
| anti-TCR monoclonal antibodies / Medigene, German Research Center for Environmental Health, Max Delbrück Centre for Molecular Medicine (0 Trials) |
|
| Anti-thymocyte globulin / Grifols (0 Trials) |
|
| anti-TIGIT antibody / Tikcro Technologies (0 Trials) |
|
| anti-TIM-3 mAb / North Coast Biologics (0 Trials) |
|
| anti-TNF/IL-17A FynomAb (COVA322) / J&J (0 Trials) |
|
| anti-trkC mAb / NETRIS Pharma (0 Trials) |
|
| Anti-viroporin therapeutics / Biotron (0 Trials) |
|
| Anti-Zika IgG / Kamada (0 Trials) |
|
| antibody recruiting molecule NK cell combination therapy / Green Cross Cell, Portage (0 Trials) |
|
| antibody recruiting molecule taniraleucel combination therapy / Celularity, Portage (0 Trials) |
|
| antibody rich plasma / Ain Shams University (0 Trials) |
|
| antibody-based NK cell stimulant cancer therapeutics / Affimed, Roche (0 Trials) |
|
| ANTICA-201 / Protheragen (0 Trials) |
|
| ANTICA-201 based CART / Protheragen (0 Trials) |
|
| anticancer gene therapy / Takara (0 Trials) |
|
| AntiCovir (interferon a2b inhalation) / BetterLife Pharma (0 Trials) |
|
| antidiabetic/metabolic therapy program / Lundbeck (0 Trials) |
|
| Antiferon (interferon alpha kinoid) / Neovacs (1 Trials) |
|
| ANTIGN-109 / Protheragen (0 Trials) |
|
| antihypertensives (NicOx-3) / Nicox (0 Trials) |
|
| Antilfa (odulimomab) / Sanofi (0 Trials) |
|
| antimycon (AMINI77) / Statera BioPharma (0 Trials) |
|
| AntionkoRAN-M (stimotimagene сopolymerplasmid) / Gene Surgery (0 Trials) |
|
| antisense LNA (EZN-3042) / Enzon (0 Trials) |
|
| antisense LNA (EZN-4176) / Enzon (0 Trials) |
|
| antisense oligonucleotide based coronovirus therapy / Sun Yat-sen University, Secarna (0 Trials) |
|
| antisense oligonucleotide therapy / Sarepta Therap (0 Trials) |
|
| antisense oligonucleotides for epilepsy / Q-State Biosci (0 Trials) |
|
| antithrombotic / Shifa Biomedical Corp (0 Trials) |
|
| antiviral therapeutics / Cyclica, Chinese Academy of Medical Sciences (0 Trials) |
|
| Antova (ruplizumab) / Biogen (0 Trials) |
|
| Antrastuin (trastuzumab biosimilar) / Anhui Anke Biotech (0 Trials) |
|
| anumigilimab (CSL324) / CSL Behring (1 Trials) |
|
| ANV-201 / Anvil Biosci (0 Trials) |
|
| ANV419 / Anaveon (0 Trials) |
|
| anvatabart opadotin (JNJ-0683) / J&J (18 Trials) |
|
| ANVS405 / Annovis Bio (0 Trials) |
|
| ANX-042 / Anexon (1 Trials) |
|
| ANX005 / Annexon Biosci (0 Trials) |
|
| ANX007 / Annexon Biosci (0 Trials) |
|
| ANX009 / Annexon Biosci (0 Trials) |
|
| ANX105 / Annexon Biosci (0 Trials) |
|
| ANX1502 / Annexon Biosci (0 Trials) |
|
| ANXV / Annexin (1 Trials) |
|
| Anyara (naptumomab estafenatox) / NeoTX (1 Trials) |
|
| anzurstobart (BMS-986351) / BMS (0 Trials) |
|
| AO-176 / Arch Oncology (0 Trials) |
|
| AOC-DMD exon 45 skipping program / Eli Lilly (0 Trials) |
|
| AOC-DMD exon 51 skipping program / Eli Lilly, Avidity Biosci (0 Trials) |
|
| AOC-Pompe Disease / Eli Lilly, Avidity Biosci (0 Trials) |
|
| AON-D21 / Aptarion (0 Trials) |
|
| AOP-208 / AOP Orphan Pharma, Leukos Biotech (0 Trials) |
|
| AOVA-10/20 (atorvastatin) / Aamorb Pharma (0 Trials) |
|
| AP 1102 / Action Pharma (0 Trials) |
|
| AP-002 / BetterLife Pharma (0 Trials) |
|
| AP-101 / AL-S Pharma (0 Trials) |
|
| AP-2600 / Arissa (0 Trials) |
|
| AP-472 / Appello Pharma (0 Trials) |
|
| AP-768 / Boehringer Ingelheim (0 Trials) |
|
| AP-PA02 / Armata (0 Trials) |
|
| AP-PA03 / Armata (0 Trials) |
|
| AP-SA01 / Armata (1 Trials) |
|
| AP-SA02 / Armata (0 Trials) |
|
| AP001 / Anida Pharma (0 Trials) |
|
| AP032 (darbepoetin alfa biosimilar) / Aprogen, Nichi-Iko, Sanofi (0 Trials) |
|
| AP05 (rituximab biosimilar) / Aprogen, Nichi-Iko (0 Trials) |
|
| AP06 (trastuzumab biosimilar) / Aprogen, Sanofi (0 Trials) |
|
| AP10 / Aprogen (0 Trials) |
|
| AP1030 / Action Pharma (0 Trials) |
|
| AP105 / AP Biosciences (0 Trials) |
|
| AP116 / AP Biosciences (0 Trials) |
|
| AP163 / Lunan Pharma, Ampsource Biopharma (0 Trials) |
|
| AP203 / AP Biosciences (0 Trials) |
|
| AP303 / Alebund (0 Trials) |
|
| AP30663 / Acesion (0 Trials) |
|
| AP405 / Action Pharma (0 Trials) |
|
| AP505 / AP Biosciences (0 Trials) |
|
| AP60 / Aprogen (0 Trials) |
|
| AP70 / Aprogen (0 Trials) |
|
| apabetalone (RVX 208) / Resverlogix (3 Trials) |
|
| Apadaz (benzhydrocodone/acetaminophen) / Zevra Therap, KVK Tech, Sure Med Compliance (0 Trials) |
|
| apalutamide / Generic mfg. (82 Trials) |
|
| apararenone (MT-3995) / Mitsubishi Tanabe (0 Trials) |
|
| Apatone B (ascorbic acid/menadione) / Summa Health, IC-MedTech (0 Trials) |
|
| apatorsen (OGX-427) / Achieve Life Sciences (1 Trials) |
|
| Apaza (mesalamine/4-aminophenylacetic acid) / 9 Meters Biopharma (0 Trials) |
|
|